Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).
Stefan Hubert Boeck
Honoraria - Roche
Research Funding - Roche
Steffen Ormanns
No relevant relationships to disclose
Ruediger Paul Laubender
No relevant relationships to disclose
Andreas Jung
No relevant relationships to disclose
Jens T Siveke
No relevant relationships to disclose
Michael Haas
No relevant relationships to disclose
Jens Neumann
No relevant relationships to disclose
Ursula Vehling-Kaiser
No relevant relationships to disclose
Cornelia Winkelmann
No relevant relationships to disclose
Ludwig Fischer von Weikersthal
No relevant relationships to disclose
Michael R. Clemens
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
Thomas C. Gauler
No relevant relationships to disclose
Angela Marten
No relevant relationships to disclose
Stefan Klein
No relevant relationships to disclose
Georgi Kojouharoff
No relevant relationships to disclose
Michael Geissler
No relevant relationships to disclose
Tim F Greten
No relevant relationships to disclose
Thomas Kirchner
No relevant relationships to disclose
Volker Heinemann
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche